Drug intelligence / Profile preview

RSQ-020

Development stage: Preclinical
Lead developer: ResQ Biotech
Modality: Peptides
Administration: Parenteral

Overview

RSQ-020 (also known as RSQ-tau) is a brain-penetrant cyclic oligopeptide developed by ResQ Biotech as a pharmacological chaperone for the treatment of Alzheimer's disease and other tauopathies. Designed using the company's CycloFOLDER macrocycle platform, RSQ-020 is engineered to prevent and reverse pathological tau misfolding and aggregation. In preclinical studies, the candidate has demonstrated the ability to disassemble tau fibrillar aggregates from human Alzheimer's and Pick's disease brains, as well as restore lifespan, learning, and memory in drosophila models of tauopathy.

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on RSQ-020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSQ-020.

Explore the full profile